Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
Conditions:   Platinum-resistant Ovarian Cancer;   Platinum-refractory Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   High-grade Serous Ovarian Cancer;   Endometrioid Ovarian Cancer;   Ovarian Clear Cell Carcinoma
Interventions:   Biological: olvimulogene nanivacirepvec;   Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin;   Drug: Non-platinum chemotherapy: Physician’s Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;   Drug: Bevacizumab (or biosimilar)
Sponsors:   Genelux Corporation;   GOG Foundation
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 7, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments